<DOC>
	<DOCNO>NCT01078168</DOCNO>
	<brief_summary>The trial investigate change cerebral spinal fluid APPSα level oral therapy acitretin 30mg daily patient mild moderate Alzheimer 's disease.The present study aim demonstrate enhancement α-secretase activity acitretin measure increased CSF APPSα level human AD . Second , safety tolerability acitretin AD patient proven .</brief_summary>
	<brief_title>Alzheimer ` Disease Acitretin Medication</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>mild moderate AD ( NINCDSADRDA criterion ) MMSE : 2714 point Geriatric Depression Scale ≤ 14 hereditary cognitive impairment know history brain injury Insufficient German language skill actual treatment potential disease modify drug AD multimorbidity significant organ ( esp . liver renal ) dysfunction evidence NonAD neurodegenerative disorder ( e.g . Parkinson ) contraindication acitretin osteoporosis , hypoalbuminaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Alzheimer ` Disease</keyword>
</DOC>